Quick Answer
Inhibitor Therapeutics, Inc. reported R&D Expense of $1.70 million for fiscal year 2025.
Inhibitor Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.70M | -3.5% |
| 2024 | $1.76M | +27.3% |
| 2023 | $1.38M | +22356.4% |
| 2022 | $6.2K | +25.4% |
| 2021 | $4.9K | -97.4% |
| 2020 | $185.3K | -84.7% |
| 2019 | $1.21M | -54.1% |
| 2018 | $2.63M | +18.2% |
| 2017 | $2.23M | -15.7% |
| 2016 | $2.64M | +57.2% |
| 2015 | $1.68M | -30.9% |
| 2014 | $2.43M | +128.2% |
| 2013 | $1.07M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $377.8K | +2.2% | +16.0% |
| June 30, 2025 | $325.6K | +35.8% | +37.9% |
| March 31, 2025 | $236.1K | -9.3% | -36.1% |
| September 30, 2024 | $369.6K | +41.7% | +54.2% |
| June 30, 2024 | $239.8K | +2.5% | -7.9% |
| March 31, 2024 | $260.4K | +29.3% | -0.2% |
| September 30, 2023 | $260.8K | — | +11.4% |
| June 30, 2023 | $234.0K | +3704.8% | +16.2% |
- Inhibitor Therapeutics, Inc. showed a decrease of -3.5% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Inhibitor Therapeutics, Inc.’s r&d expense has grown by 59.3% (from $1.07 million to $1.70 million).
- The most recent figure is from Inhibitor Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: